Premium
Asia Pacific perspectives on the second year of the COVID ‐19 pandemic: A follow‐up survey
Author(s) -
Pawankar Ruby,
Thong Bernard YuHor,
TiongcoRecto Marysia,
Wang JiuYao,
Latiff Amir Hamzah Abdul,
Leung Ting Fan,
Li Philip Hei,
Lobo Rommel Crisenio M.,
Lucas Michela,
Oh JaeWon,
Kamchaisatian Wasu,
Nagao Mizuho,
Rengganis Iris,
Udwadia Zarir F.,
Dhar Raja,
Munkhbayarlakh Sonomjamts,
Narantsetseg Logii,
Pham Duy Le,
Zhang Yuan,
Zhang Luo
Publication year - 2022
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.14191
Subject(s) - covid-19 , pandemic , betacoronavirus , medicine , virology , outbreak , disease , infectious disease (medical specialty)
Background The Coronavirus disease 2019 (COVID‐19) pandemic is currently in its third year. This follow‐up survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID‐19 to compare and contrast changes in the epidemiology, clinical profile, therapeutics and public health measures of the pandemic in the Asia Pacific region. Methods A questionnaire‐based survey comprising 32 questions was electronically sent out to all 15 member countries of APAAACI using Survey Monkey® from 1 December 2021 to 28 February 2022. Results Seventeen responses were received from 14/15 (93.4%) member countries and 3 individual members. Mild‐to‐moderate COVID‐19 predominated over severe infection, largely contributed by COVID‐19 vaccination programmes in the region. The incidence of vaccine adverse reactions in particular anaphylaxis from messenger ribonucleic acid (mRNA) vaccines was no longer as high as initially anticipated, although perimyocarditis remains a concern in younger males. Novel therapeutics for mild‐to‐moderate disease including neutralizing antibodies casirivimab/imdevimab (REGEN‐COV®) and sotrovimab (Xevudy®), anti‐virals Paxlovid® (nirmatrelvir and ritonavir) and Molnupiravir pre‐exposure prophylaxis for high‐risk persons with Tixagevimab and Cilgavimab (Evusheld) are now also available to complement established therapeutics (e.g., remdesivir, dexamethasone and baricitinib) for severe disease. In the transition to endemicity, public health measures are also evolving away from containment/elimination strategies. Conclusions With access to internationally recommended standards of care including public health preventive measures, therapeutics and vaccines among most APAAACI member countries, much progress has been made over the 2‐year period in minimizing the morbidity and mortality from COVID‐19 disease.